Analysts Issue Forecasts for Chemours’ Q2 Earnings (NYSE:CC)

The Chemours Company (NYSE:CC) – Zacks Research cut their Q2 2026 EPS estimates for shares of Chemours in a report released on Monday, May 18th. Zacks Research analyst Team now anticipates that the specialty chemicals company will post earnings per share of $0.33 for the quarter, down from their previous forecast of $0.60. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $1.27 per share.

Several other equities analysts also recently issued reports on CC. Royal Bank Of Canada lifted their price objective on Chemours from $26.00 to $29.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Jefferies Financial Group restated a “hold” rating and issued a $17.00 target price on shares of Chemours in a research note on Monday, February 23rd. Truist Financial lifted their price target on Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Morgan Stanley upped their price target on shares of Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Monday, May 11th. Finally, BMO Capital Markets decreased their price objective on shares of Chemours from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Monday, February 23rd. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $23.09.

Chemours Stock Performance

NYSE:CC opened at $22.26 on Thursday. The stock has a market capitalization of $3.35 billion, a P/E ratio of -8.43 and a beta of 1.47. The company has a current ratio of 1.82, a quick ratio of 0.87 and a debt-to-equity ratio of 18.98. Chemours has a 1 year low of $9.13 and a 1 year high of $28.67. The firm has a 50 day moving average of $22.29 and a 200-day moving average of $17.25.

Chemours (NYSE:CC) last issued its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.10. The firm had revenue of $1.38 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.13 earnings per share.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Friday, May 15th. Chemours’s payout ratio is currently -13.26%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC grew its position in shares of Chemours by 10.9% during the 1st quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock worth $118,000 after buying an additional 527 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in Chemours by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock valued at $404,000 after buying an additional 600 shares during the period. Amalgamated Bank boosted its stake in Chemours by 1.7% in the third quarter. Amalgamated Bank now owns 43,528 shares of the specialty chemicals company’s stock valued at $689,000 after acquiring an additional 740 shares during the last quarter. PFG Investments LLC boosted its stake in Chemours by 7.6% in the fourth quarter. PFG Investments LLC now owns 12,494 shares of the specialty chemicals company’s stock valued at $147,000 after acquiring an additional 883 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Chemours by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 76,257 shares of the specialty chemicals company’s stock worth $899,000 after acquiring an additional 932 shares during the period. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours saw unusually heavy options activity, with traders buying 33,698 call contracts, a sharp jump versus normal volume. That can signal bullish speculation on the stock. Enlightify (NYSE:ENFY) versus Chemours (NYSE:CC) Critical Analysis
• Neutral Sentiment: Zacks Research kept a Hold rating on Chemours while adjusting several forecast periods up and down, suggesting analysts are still cautious but not outright bearish.
• Negative Sentiment: The most notable revisions were lower near-term earnings estimates, including FY2026 EPS cut to $0.90 from $1.06 and Q1 2027 EPS cut to $0.41 from $0.45, which may weigh on sentiment.
• Positive Sentiment: Some longer-dated estimates were raised, including Q3 2027 EPS to $0.57 from $0.52 and Q4 2027 EPS to $0.50 from $0.46, indicating a somewhat better outlook further out.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.